KPRX Stock Overview
A clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Kiora Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.24 |
| 52 Week High | US$8.98 |
| 52 Week Low | US$3.00 |
| Beta | -0.48 |
| 1 Month Change | 0.28% |
| 3 Month Change | -11.50% |
| 1 Year Change | -33.11% |
| 3 Year Change | -98.96% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem
May 21
Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Kiora Pharmaceuticals reports 1H results
Aug 12Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing
Jul 28Kiora Pharmaceuticals prices $5.2M underwritten public offering
Jul 22Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Jul 05EyeGate Pharmaceuticals announces $8M private placement
Jan 06EyeGate surge in premarket as it acquires Panoptes Pharma for $4M
Dec 21Shareholder Returns
| KPRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.8% | -2.0% | -3.5% |
| 1Y | -33.1% | 7.6% | 22.1% |
Return vs Industry: KPRX underperformed the US Pharmaceuticals industry which returned 9.1% over the past year.
Return vs Market: KPRX underperformed the US Market which returned 24% over the past year.
Price Volatility
| KPRX volatility | |
|---|---|
| KPRX Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KPRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KPRX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 12 | Brian Strem | www.kiorapharma.com |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
Kiora Pharmaceuticals, Inc. Fundamentals Summary
| KPRX fundamental statistics | |
|---|---|
| Market cap | US$9.78m |
| Earnings (TTM) | US$5.55m |
| Revenue (TTM) | US$16.02m |
1.8x
P/E Ratio0.6x
P/S RatioIs KPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KPRX income statement (TTM) | |
|---|---|
| Revenue | US$16.02m |
| Cost of Revenue | US$4.83m |
| Gross Profit | US$11.19m |
| Other Expenses | US$5.64m |
| Earnings | US$5.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.85 |
| Gross Margin | 69.86% |
| Net Profit Margin | 34.64% |
| Debt/Equity Ratio | 0% |
How did KPRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 01:55 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kiora Pharmaceuticals, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Yi Chen | H.C. Wainwright & Co. |
| Matthew Kaplan | Ladenburg Thalmann & Company |